GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] small community, high signal, let us keep it that way — 12 comments in the full submission. View in context.
77
c/survodutide·submitted 11 days ago by u/peak_area_pete

[Discussion] small community, high signal, let us keep it that way

Discussionbranch of 8 comments

small community, high signal, let us keep it that way. Change my mind, genuinely — I have no stake in being right about this. Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use. Imaging-derived liver fat fraction is a surrogate. It correlates with histology…

Read the full submission and all 12 comments →

This branch

8 comments, started 10 days ago
u/fibre_forward4 points·10 days ago

The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why. That is a description of the trials rather than a suggestion for anybody.

replysharereportpermalink
u/peak_area_peteOPanalytical2 points·10 days ago

What does the tolerability table say at that dose?

replysharereportpermalink
u/zeynep_villalobos1 point·10 days ago

the titration in the trials was slow and deliberate

replysharereportpermalink
u/clara_restrepo1 point·10 days ago

biopsy-confirmed is not the same as imaging-suggested

replysharereportpermalink
u/endotoxin_elliemicro1 point·9 days ago·edited

Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.

replysharereportpermalink
u/cold_chromatogram_only1 point·9 days ago

It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.

replysharereportpermalink
u/isabela_nilsen1 point·10 days ago·edited

What does the tolerability table say at that dose?

This is the framing the board needs. It is a hepatic programme first.

replysharereportpermalink
u/endotoxin_elliemicro1 point·10 days ago

Disagree — that is a weight endpoint from a different programme and you are quoting it in a hepatic context.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.